DE60020136T2 - Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell-immunantwort gegen antigen - Google Patents
Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell-immunantwort gegen antigen Download PDFInfo
- Publication number
- DE60020136T2 DE60020136T2 DE60020136T DE60020136T DE60020136T2 DE 60020136 T2 DE60020136 T2 DE 60020136T2 DE 60020136 T DE60020136 T DE 60020136T DE 60020136 T DE60020136 T DE 60020136T DE 60020136 T2 DE60020136 T2 DE 60020136T2
- Authority
- DE
- Germany
- Prior art keywords
- antigen
- administration
- immune response
- mva
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 46
- 102000036639 antigens Human genes 0.000 title claims abstract description 46
- 108091007433 antigens Proteins 0.000 title claims abstract description 46
- 230000028993 immune response Effects 0.000 title claims abstract description 31
- 239000013598 vector Substances 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title description 6
- 230000001965 increasing effect Effects 0.000 title description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 230000037452 priming Effects 0.000 claims abstract description 34
- 241000700605 Viruses Species 0.000 claims abstract description 22
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 9
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 9
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 9
- 230000002950 deficient Effects 0.000 claims abstract description 6
- 230000010076 replication Effects 0.000 claims abstract description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 41
- 238000007918 intramuscular administration Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 description 44
- 230000003053 immunization Effects 0.000 description 44
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 24
- 229960005486 vaccine Drugs 0.000 description 21
- 241000224017 Plasmodium berghei Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 230000003248 secreting effect Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 210000004988 splenocyte Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 8
- 108010041986 DNA Vaccines Proteins 0.000 description 7
- 229940021995 DNA vaccine Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000003046 sporozoite Anatomy 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 201000004792 malaria Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 101150052200 CS gene Proteins 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000010422 painting Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 208000002476 Falciparum Malaria Diseases 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 2
- 241000223830 Plasmodium yoelii Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700004715 Flavivirus NS1 Proteins 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010028253 Measles virus nucleoprotein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- -1 Petrol Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- FEBNTWHYQKGEIQ-BIMULSAOSA-N nardin Natural products C[C@H]1CC[C@H](C=C(/C)C(=O)O)C2=C(C)CC[C@@H]12 FEBNTWHYQKGEIQ-BIMULSAOSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- FEBNTWHYQKGEIQ-UHFFFAOYSA-N valerenic acid Chemical compound CC1CCC(C=C(C)C(O)=O)C2=C(C)CCC12 FEBNTWHYQKGEIQ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922361.2A GB9922361D0 (en) | 1999-09-21 | 1999-09-21 | Generating an immune response to an antigen |
| GB9922361 | 1999-09-21 | ||
| PCT/GB2000/003601 WO2001021201A2 (en) | 1999-09-21 | 2000-09-20 | Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60020136D1 DE60020136D1 (de) | 2005-06-16 |
| DE60020136T2 true DE60020136T2 (de) | 2006-02-23 |
Family
ID=10861351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60020136T Revoked DE60020136T2 (de) | 1999-09-21 | 2000-09-20 | Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell-immunantwort gegen antigen |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1612269A1 (enExample) |
| JP (1) | JP2003509470A (enExample) |
| CN (1) | CN1391609A (enExample) |
| AT (1) | ATE295421T1 (enExample) |
| AU (1) | AU762894B2 (enExample) |
| BR (1) | BR0014138A (enExample) |
| CA (1) | CA2384806A1 (enExample) |
| DE (1) | DE60020136T2 (enExample) |
| DK (1) | DK1214416T3 (enExample) |
| ES (1) | ES2241653T3 (enExample) |
| GB (1) | GB9922361D0 (enExample) |
| WO (1) | WO2001021201A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| JP2003530307A (ja) | 1999-07-06 | 2003-10-14 | メルク・アンド・カンパニー・インコーポレーテッド | ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| JP4654026B2 (ja) * | 2002-05-20 | 2011-03-16 | 独立行政法人科学技術振興機構 | Ｂｃｇワクチンとその利用 |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| CN100410382C (zh) * | 2006-08-18 | 2008-08-13 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的共表达载体和真核表达载体 |
| JP5646851B2 (ja) * | 2006-11-17 | 2014-12-24 | ジェネトロニクス，インコーポレイティド | エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法 |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| CA2699465C (en) * | 2007-09-14 | 2017-11-28 | Institut Pasteur | Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use |
| GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| MX380483B (es) * | 2012-10-28 | 2025-03-12 | Bavarian Nordic As | Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes. |
| EP3595705A1 (en) | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| MX2022004484A (es) * | 2019-10-16 | 2022-07-19 | Cancer Research Tech Ltd | Vector para el tratamiento de cancer. |
| EP4444347A1 (en) | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
| WO2024218165A1 (en) | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
-
1999
- 1999-09-21 GB GBGB9922361.2A patent/GB9922361D0/en not_active Ceased
-
2000
- 2000-09-20 BR BR0014138-0A patent/BR0014138A/pt not_active Application Discontinuation
- 2000-09-20 CA CA002384806A patent/CA2384806A1/en not_active Abandoned
- 2000-09-20 ES ES00960857T patent/ES2241653T3/es not_active Expired - Lifetime
- 2000-09-20 WO PCT/GB2000/003601 patent/WO2001021201A2/en not_active Ceased
- 2000-09-20 AU AU73024/00A patent/AU762894B2/en not_active Ceased
- 2000-09-20 EP EP05009308A patent/EP1612269A1/en not_active Withdrawn
- 2000-09-20 DE DE60020136T patent/DE60020136T2/de not_active Revoked
- 2000-09-20 JP JP2001524625A patent/JP2003509470A/ja not_active Withdrawn
- 2000-09-20 AT AT00960857T patent/ATE295421T1/de not_active IP Right Cessation
- 2000-09-20 EP EP00960857A patent/EP1214416B1/en not_active Revoked
- 2000-09-20 CN CN00815933A patent/CN1391609A/zh active Pending
- 2000-09-20 DK DK00960857T patent/DK1214416T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| BR0014138A (pt) | 2002-05-21 |
| WO2001021201A3 (en) | 2001-10-18 |
| DK1214416T3 (da) | 2005-08-29 |
| DE60020136D1 (de) | 2005-06-16 |
| CA2384806A1 (en) | 2001-03-29 |
| JP2003509470A (ja) | 2003-03-11 |
| EP1612269A1 (en) | 2006-01-04 |
| EP1214416A2 (en) | 2002-06-19 |
| AU7302400A (en) | 2001-04-24 |
| EP1214416B1 (en) | 2005-05-11 |
| ATE295421T1 (de) | 2005-05-15 |
| AU762894B2 (en) | 2003-07-10 |
| CN1391609A (zh) | 2003-01-15 |
| GB9922361D0 (en) | 1999-11-24 |
| ES2241653T3 (es) | 2005-11-01 |
| WO2001021201A2 (en) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69839359T2 (de) | Verfahren und Reagenzien zur Erzeugung einer CD8+T-Zellen Immunantwort gegen Hepatitis B oder C | |
| DE69733145T2 (de) | Verfahren zur behandlung von allergischen lungenkrankheiten | |
| DE69815692T2 (de) | Öl in wasser emulsionen mit saponinen | |
| DE69417063T2 (de) | Impfstoffe | |
| DE60113512T2 (de) | Veränderter stamm des modifizierten vaccinia-virus ankara (mva) | |
| EP1214416B1 (en) | Use of replication-deficient adenoviral vector in the manufacture of a medicament to boost cd8+ t cell immune response to antigen | |
| DE69534250T2 (de) | Polynukleotidimpfstoff gegen tbc | |
| DE60116371T2 (de) | Variante des modifizierten vaccinia ankara virus | |
| DE69435010T2 (de) | Verfahren und stoffe für die behandlung von individuen, die infiziert sind mit intrazellulär infektiösen agentien | |
| DE69225710T2 (de) | Anregung von antworten zytotoxischer t-lymphozyten | |
| DE3751664T2 (de) | Rekombinanter impfstoff | |
| DE69715879T2 (de) | Intradermaler polynukleotid-impfstoff aus rind | |
| DE69706593T2 (de) | Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier | |
| DE3789082T2 (de) | Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors. | |
| DE102004049223A1 (de) | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung | |
| DE69232890T2 (de) | Regulierung der systemischen immunantworten mittels zytokinen und antigenen | |
| DE69400312T2 (de) | Zusammensetzung bestehend aus einem rekombinanten lebenden untereinheitsimpfstoff und verfahren zur herstellung | |
| DE69515340T2 (de) | Impfstoff gegen mycobakterielle infektionen | |
| WO1996005866A2 (de) | Lebendvakzine zur behandlung von tumorerkrankungen | |
| DE69929432T2 (de) | Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins | |
| EP1615663B1 (de) | Mittel zur behandlung von infektionen mit leishmanien | |
| DE69514217T2 (de) | Rekombinante plasmide enthaltende zusammensetzung und ihre verwendung als impstoff und arzneimittel | |
| EP1504107A1 (de) | Rekombinantes fowlpox-virus | |
| US20100322896A1 (en) | Molecular adjuvant | |
| DE69428984T2 (de) | Stimulierung der immunantwort durch virales protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |